Opendata, web and dolomites

EQIPD SIGNED

European Quality In Preclinical Data

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EQIPD project word cloud

Explore the words cloud of the EQIPD project. It provides you a very rough idea of what is the project "EQIPD" about.

training    patent    basic    pool    market    freedom    neuroscience    relevance    publications    governance    psychosis    informed    contributions    educational    components    sustainability    pilot    recommendations    review    prospective    attest    rigor    action    site    patients    online    disease    pharmaceutical    certified    applicability    eqipd    neuro    exchange    criteria    sustainable    preclinical    historical    compliance    gain    science    validate    platform    innovation    alzheimer    variables    experiments    ring    cross    strength    influence    effect    succeed    regulated    consensus    pivotal    drivers    decisions    community    outcome    junior    core    cultural    clinical    principles    predictability    industry    data    form    delphi    education    enrolled    feasibility    impacting    treatments    systematic    rigour    solutions    models    infrastructure    scientific    policy    turn    decision    academia    emerge    outcomes    meta    quality    made    validity    framework    expansion    report    safety    robustness    members    scheme    joint    time    ripple   

Project "EQIPD" data sheet

The following table provides information about the project.

Coordinator
THE UNIVERSITY OF EDINBURGH 

Organization address
address: OLD COLLEGE, SOUTH BRIDGE
city: EDINBURGH
postcode: EH8 9YL
website: www.ed.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.eqipd.org
 Total cost 9˙845˙483 €
 EC max contribution 4˙495˙523 € (46%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2016-09-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2017
 Duration (year-month-day) from 2017-10-01   to  2020-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE UNIVERSITY OF EDINBURGH UK (EDINBURGH) coordinator 849˙133.00
2    RIJKSUNIVERSITEIT GRONINGEN NL (GRONINGEN) participant 456˙524.00
3    THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN UK (ABERDEEN) participant 409˙110.00
4    IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE UK (LONDON) participant 371˙072.00
5    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 368˙299.00
6    PAASP GMBH DE (HEIDELBERG) participant 362˙337.00
7    EBERHARD KARLS UNIVERSITAET TUEBINGEN DE (TUEBINGEN) participant 301˙800.00
8    CHARITE - UNIVERSITAETSMEDIZIN BERLIN DE (BERLIN) participant 292˙502.00
9    Concentris Research Management GmbH DE (Fürstenfeldbruck) participant 232˙787.00
10    STICHTING KATHOLIEKE UNIVERSITEIT NL (NIJMEGEN) participant 200˙414.00
11    PORSOLT SAS FR (LE GENEST SAINT-ISLE) participant 115˙628.00
12    SYNAPTOLOGICS BV NL (AMSTERDAM) participant 110˙628.00
13    STICHTING BURO ECNP NL (UTRECHT) participant 98˙305.00
14    NOLDUS INFORMATION TECHNOLOGY BV NL (WAGENINGEN) participant 89˙152.00
15    PHARMALEX BELGIUM BE (MONT SAING GUIBERT) participant 89˙152.00
16    UNIVERSITAET BERN CH (BERN) participant 88˙672.00
17    UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ DE (Mainz) participant 60˙000.00
18    ABBVIE INC US (NORTH CHICAGO IL) participant 0.00
19    ARLENDA SA BE (MONT-SAINT-GUIBERT) participant 0.00
20    BOEHRINGER INGELHEIM INTERNATIONALGMBH DE (INGELHEIM) participant 0.00
21    F. HOFFMANN-LA ROCHE AG CH (BASEL) participant 0.00
22    INSTITUT DE RECHERCHES SERVIER FR (SURESNES) participant 0.00
23    JANSSEN PHARMACEUTICA NV BE (BEERSE) participant 0.00
24    NOVARTIS PHARMA AG CH (BASEL) participant 0.00
25    ORION OYJ FI (ESPOO) participant 0.00
26    PFIZER LIMITED UK (SANDWICH) participant 0.00
27    PSYCHOGENICS INC US (TARRYTOWN) participant 0.00
28    SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT FR (Chilly Mazarin) participant 0.00
29    SCIENCE EXCHANGE, INC. US (PALO ALTO) participant 0.00
30    UCB BIOPHARMA SRL BE (BRUXELLES) participant 0.00

Map

 Project objective

Pharmaceutical industry, as well as basic science, depend on robust data and scientific rigor as key drivers for decision making, patent strength and time-to-market, which in turn will determine knowledge gain and availability of new treatments to patients. Recent publications report challenges with the robustness, rigor, and/or validity of research data, which may impact decisions about whether to proceed to preclinical and clinical testing as well as conclusions on the predictability of preclinical models. There is a need for simple, sustainable solutions that facilitate data quality. We will propose simple, sustainable solutions that facilitate data quality without impacting innovation and freedom of research. Our consortium will pool resources from both academia and industry to pilot this action in Neuroscience and Safety, but with applicability beyond these R&D areas. The European Quality In Preclinical Data (EQIPD) consortium will (i) define those variables in study design and data analysis that influence outcome in pre-clinical neuroscience (focus on Alzheimer’s disease and psychosis) and (neuro-)safety studies conducted in industry; and establish whether these are the same variables which influence outcome in academia; (ii) define the components which will make up the EQIPD quality management system; (iii) define consensus quality management recommendations for non-regulated R&D; (iv) validate the feasibility of the quality management system in prospective studies; (v) deliver an online educational platform providing certified education and training in the principles and application of quality and rigour. We will use systematic review and meta-analysis of historical data sets from industry and academia to identify variables of study design which determine outcomes in preclinical studies. Informed by the outcome of these analyses, we will use a Delphi approach to reach consensus around core principles for preclinical robustness, validate these approaches in cross site experiments and establish ring testing experiments in non-regulated research. We will develop a quality system framework to attest to compliance and a governance system to ensure sustainability and relevance. We will develop an educational platform to ensure research community-wide expansion of knowledge on criteria and principles necessary to address robustness and quality. Junior researchers are involved in many of the tasks and are enrolled in an academia/industry joint exchange scheme. They will form the core from where a cultural change should emerge in form of a ripple effect. Consortium members have made pivotal scientific and policy contributions relating to the robustness, rigor and validity of pre-clinical research in the past and together have the know-how and infrastructure necessary to succeed in this highly ambitious project.

 Deliverables

List of deliverables.
Structure and first incentives for electronic community enabling social learning, hosted on a web-based platform Other 2020-04-09 02:16:09
With input from WPs 2 and 3 develop harmonized protocols for cross validation testing Documents, reports 2020-04-09 02:16:09
Evaluation of existing training modules Documents, reports 2020-04-09 02:16:09
Outcome report from cross site validation Documents, reports 2020-04-09 02:16:09
Data inclusion protocol Open Research Data Pilot 2020-04-09 02:16:09
Release of project website public and internal part, communication package (logo, flyer, social media announcement Websites, patent fillings, videos etc. 2020-04-09 02:16:09
1st Technical diagram of EQIPD-DWH Other 2020-04-09 02:16:09
Obtain ethical approval for cross-site validation studies and ring testing Documents, reports 2020-04-09 02:16:09
First quarterly electronic bulletins online Websites, patent fillings, videos etc. 2020-04-09 02:16:09
First press release Websites, patent fillings, videos etc. 2020-04-09 02:16:09

Take a look to the deliverables list in detail:  detailed list of EQIPD deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Martin C. Michel, T.J. Murphy, Harvey J. Motulsky
New Author Guidelines for Displaying Data and Reporting Data Analysis and Statistical Methods in Experimental Biology
published pages: 64-74, ISSN: 0090-9556, DOI: 10.1124/dmd.119.090027
Drug Metabolism and Disposition 48/1 2020-04-09
2019 Martin C. Michel, T.J. Murphy, Harvey J. Motulsky
New Author Guidelines for Displaying Data and Reporting Data Analysis and Statistical Methods in Experimental Biology
published pages: 136-147, ISSN: 0022-3565, DOI: 10.1124/jpet.119.264143
Journal of Pharmacology and Experimental Therapeutics 372/1 2020-04-09
2019 Marjan Amiri, Sandra Murgas, Andreas Stang, Martin C. Michel
Do overactive bladder symptoms and their treatment‐associated changes exhibit a normal distribution? Implications for analysis and reporting
published pages: 754-761, ISSN: 0733-2467, DOI: 10.1002/nau.24275
Neurourology and Urodynamics 39/2 2020-04-09
2019 Anton Bespalov, Thomas Steckler, Phil Skolnick
Be positive about negatives–recommendations for the publication of negative (or null) results
published pages: 1312-1320, ISSN: 0924-977X, DOI: 10.1016/j.euroneuro.2019.10.007
European Neuropsychopharmacology 29/12 2020-04-09
2019 Martin C. Michel, T.J. Murphy, Harvey J. Motulsky
New Author Guidelines for Displaying Data and Reporting Data Analysis and Statistical Methods in Experimental Biology
published pages: 49-60, ISSN: 0026-895X, DOI: 10.1124/mol.119.118927
Molecular Pharmacology 97/1 2020-04-09
2020 Betul R. Erdogan, Irem Karaomerlioglu, Zeynep E. Yesilyurt, Nihal Ozturk, A. Elif Muderrisoglu, Martin C. Michel, Ebru Arioglu-Inan
Normalization of organ bath contraction data for tissue specimen size: does one approach fit all?
published pages: 243-251, ISSN: 0028-1298, DOI: 10.1007/s00210-019-01727-x
Naunyn-Schmiedeberg\'s Archives of Pharmacology 393/2 2020-04-09
2018 Steckler, T., Macleod, M., Kas, M. J. H., Gilis, A., & Wever, K. E.
European Quality in Preclinical Data (EQIPD): Een breed consortium voor het verbeteren van de kwaliteit van proefdieronderzoek.
published pages: 18-23, ISSN: 0166-6207, DOI:
Biotechniek 57 (2) 2020-04-09
2018 Harvey J Motulsky, Martin C Michel
Commentary on the BJP \'s new statistical reporting guidelines
published pages: 3636-3637, ISSN: 0007-1188, DOI: 10.1111/bph.14441
British Journal of Pharmacology 175/18 2020-04-09
2018 Jan Vollert, Esther Schenker, Malcolm Macleod, Anton Bespalov, Hanno Wuerbel, Martin Christian Michel, Ulrich Dirnagl, Heidrun Potschka, Kimberley E Wever, Thomas Steckler, Bruce Altevogt, Andrew S C Rice
Protocol for a systematic review of guidelines for rigour in the design, conduct and analysis of biomedical experiments involving laboratory animals
published pages: e000004, ISSN: 2398-8703, DOI: 10.1136/bmjos-2018-000004
BMJ Open Science 2/1 2020-04-09

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EQIPD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EQIPD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

PD-MIND (2019)

Parkinson Disease with Mild cognition Impairment treated with Nicotinic agonist Drug

Read More  

RespiriTB (2019)

Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors

Read More